GLP1R and type 2 diabetes mellitus: Table 3 summarizes the ceramides’ profiles evaluated in the discussed T2DM and IR studies. Interestingly in this context, very recent data show that liraglutide (a GLP-1 receptor agonist) decreased ceramide levels, suggesting downstream effects of liraglutide on lipid metabolism that could benefit the cardiovascular profile in type 2 diabetes patients [77].